UNSPSC 51295104: Fantridone

This classification denotes an antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S5M8L6357X. European Medicines Agency schedules Fantridone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07511MIG. Fantridone generally arises in the molecular formula C18H20N2O.

UNSPSC 51295104 Fantridone is a Commodity code under which state and local governments procure pharmaceutical products and drug-related public health supplies, including naloxone, safe drug deactivation systems, and generic multi-source pharmaceuticals distributed through established wholesaler networks and cooperative purchasing vehicles. The work encompasses both direct procurement of finished pharmaceutical inventory for community health programs and participation in multi-state cooperative agreements that establish pricing and supply relationships with pharmaceutical manufacturers and distributors. Issuing bodies span county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances administering shared procurement on behalf of participating state and local jurisdictions.

Recent activity appears concentrated in the Southeast and upper Midwest. Seminole County, Florida issued IFB 60459723LAS in June 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, closing July 26, 2023 (note: the source contains a date inconsistency), on a fixed-fee basis with a two-year initial term and one-year renewal option. Texas HHS Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for a direct-to-manufacturer prescription program outside traditional pharmacy benefit manager and group purchasing organization channels, targeting direct contracting with self-insured employers and state agencies. Minnesota's multistate cooperative purchasing alliance (MMCAP) issued RFP S1070000015802 in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products distributed across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. Vendors must comply with cGMP and Drug Supply Chain Security Act (DSCSA) standards, maintain relationships with authorized wholesalers, and carry commercial general liability coverage of $5,000,000 per occurrence.